Harnessing Computational/AI to Shape the Next Generation of Peptide-based Drug Discovery

Peptide therapeutics represent a groundbreaking approach in the biopharmaceutical industry, providing innovative solutions for various medical conditions, including the treatment of metabolic diseases. The global peptide therapeutics market is projected to reach $117.4 billion by 2034, with a compound annual growth rate (CAGR) of 10.8%. Recent advancements in technologies such as computational AI/ML and robust prediction of protein structure for developing clinical candidates are showing promising progress, but we are still in the early stages. This presentation will cover (a) traditional drug discovery overview for first-in-Class GLP-1 drugs for metabolic Diabetes and Obesity and (b) how ML/AI techniques are transforming the quality, speed and cost for drug discovery of novel peptide drug discovery for diabetes and cancer.